Harmony Biosciences Holdings (HRMY) Raw Materials (2023 - 2024)
Harmony Biosciences Holdings (HRMY) posted Raw Materials of $944000.0 for Q4 2024, down 8.62% sequentially from $1.0 million in Q3 2024, and down 10.94% YoY from $1.1 million in Q1 2024.
Harmony Biosciences Holdings (HRMY) Raw Materials (2023 - 2024) Analysis & Trends
Harmony Biosciences Holdings has reported Raw Materials for 2 years, with the latest figure at $944000.0 in Q4 2024.
- Quarterly Raw Materials fell 10.94% year-over-year to $944000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $944000.0 (down 10.94% YoY) and the FY2024 annual result came in at $944000.0, down 10.94% from the prior year.
- Raw Materials retreated to $944000.0 in Q4 2024 per HRMY's latest filing, from $1.0 million in the prior quarter.
- Over five years, Raw Materials peaked at $1.1 million in Q2 2024 and troughed at $944000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 944,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 1.06 Mn |